Standards of medical care for patients with diabetes mellitus

Diabetes Care

Volumn 25, Issue SUPPL. 1, 2002, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DISEASE CLASSIFICATION; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MASS SCREENING; MEDICAL CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; REVIEW; RISK FACTOR; STANDARD;

EID: 23944513384     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.2007.s33     Document Type: Review

References (91)

1. Skyler JS (Ed.): Medical Management of Type 1 Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 1998
2. Zimmerman BR (Ed.): Medical Management of Type 2 Diabetes. 4th ed. Alexandria, VA, American Diabetes Association, 1998
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 25 (Suppl. 1):S5-S20,2002
4. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no.727)
5. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaaniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
6. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The DaQing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
7. Available on the internet, www.prevent diabetes.com. Accessed October 2001
8. Engelgau ME, Narayan KMV, Herman WH: Screening for type 2 diabetes (Technical Review). Diabetes Care 10:1563-1580, 2000
9. American Diabetes Association: Type 2 diabetes in children and adolescents (Consensus Statement). Diabetes Care 23: 381-389, 2000
10. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S94-S96, 2002
11. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
12. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
13. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UK-PDS 34). Lancet 352:854-865, 1998
14. Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diabetes Care 22 (Suppl. 1):B35-B39, 1999
15. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
16. American Diabetes Association: Postprandial blood glucose (Consensus Statement). Diabetes Care 24:775-778, 2001
17. Jovanovic L (Ed.): Medical Management of Pregnancy Complicated by Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 2000
18. American Diabetes Association: Management of hyperglycemic crises in patients with diabetes (Position Statement). Diabetes Care 25 (Suppl. 1): S100-S108, 2002
19. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 17:81-86, 1994
20. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 10:93-99, 1987
21. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister L, Hoogwerf BJ, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Technical Review). Diabetes Care 25: 148-198, 2002
22. American Diabetes Association: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Position Statement). Diabetes Care 25 (Suppl. 1):S50-S60, 2002
23. Schneider SH, Ruderman NB: Exercise and NIDDM (Technical Review). Diabetes Care 13:785-789, 1990
24. Wasserman DH, Zinman B: Exercise in individuals with IDDM (Technical Review). Diabetes Care 17:924-937, 1994
25. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes mellitus (Technical' Review). Diabetes Care 25:134-147, 2002
26. Haffner SM: Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 21:160-178, 1998
27. Colwell JA: Aspirin therapy in diabetes (Technical Review). Diabetes Care 20: 1767-1771, 1997
28. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes (Technical Review). Diabetes Care 22:1887-1898, 1999
29. American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Diabetes Care 21:1551-1559, 1998
30. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Int Med 157:2413-2446, 1997
31. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
32. Hansson L, Zanchett A, Carruthers SG, et al: Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351:1755-1762, 1998
33. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997
34. Tatti P, Paahron M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998
35. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-654, 1998
36. Messerli FH: Implications of discontinuation of doxazosin arm of ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Lancet 355:863-864, 2000
37. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Study (4S). Diabetes Care 20:614-620, 1997
38. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Wamica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction I patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 335:1001-1009, 1996
39. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339:1349-1357, 1998
40. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Getto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279:1615-1622, 1998
41. 4L Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence, of coronary heart disease. N Engl J Med 317: 1237-1245, 1987
42. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
43. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284: 1263-1270, 2000
44. Expert Panel on Blood Cholesterol Levels in Children and Adolescents: Treatment recommendations of the National Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 89 (Suppl.):525-584, 1992
45. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
46. Peterson JG, Topol EJ, Sapp SK, Young JB, Lincoff AM, Lauer MS: Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med 109:371-377, 2000
47. U.S: Preventive Services Task Force: Counseling to prevent tobacco use. In Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD, Williams & Wilkins, 1996, p. 597-609
48. Fiore M, Bailey W, Cohen S: Smoking Cessation: Clinical Practice Guideline Number 18. Rockville, MD, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996
49. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
50. The DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 47:1703-1720, 1995
51. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
52. Laffel LMB, McGill JB, Gans DJ, and the North American Microalbuminuria Study Group (NAMSG): The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-504, 1995
53. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 128:982-988, 1998
54. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156:286-289, 1996
55. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 355:253-259, 2000
56. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
57. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
58. Parving HH, Lehnen H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
59. Anderson S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
60. American Diabetes Association: Diabetic nephropathy (Position Statement). Diabetes Care 25 (Suppl. 1):S85-S89, 2002
61. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM: Preventive foot care in people with diabetes (Technical Review). Diabetes Care 21:2161-2177, 1998
62. American Diabetes Association: Preventive foot care in people with diabetes (Position Statement). Diabetes Care 25 (Suppl. 1):S69-S70, 2002
63. American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Statement). Diabetes Care 22:1354-1360, 1999
64. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Diabetic retinopathy (Technical Review). Diabetes Care 21:143-156, 1998
65. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 23:1084-1091, 2000
66. Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383-396, 1976
67. Diabetic Retinopathy Study Research Group: Four risk factors for severe visual loss in diabetic retinopathy: the third report of the Diabetic Retinopathy Study. Arch Opthalmol 97:654-655, 1979
68. Diabetic Retinopathy Study Research Group: Design, methods, and baseline results: DRS report no. 6. Invest Ophthalmol Vis Sci 21:149-209, 1981
69. Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS report number 8. Opthalmology 88:583-600, 1981
70. Diabetic Retinopathy Study Research Group: Indications for photocoagulation treatment of diabetic retinopathy: DRS report no. 14. Int Opthalmol Clin 27:239-253, 1987
71. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 1. Arch Opthalmol 103:1796-1806, 1985
72. Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: ETDRS report number 2. Opthalmology 94:761-774, 1987
73. Early Treatment Diabetic Retinopathy Study Research Group: Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS report no. 3. Int Ophthalmol Clin 27:254-264, 1987
74. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. ETDRS report no. 4. Int Opthalmol Clin 27:265-272, 1987
75. Early Treatment Diabetic Retinopathy: Study design and baseline patient characteristics: ETDRS report number 7. Opthalmology 98:741-756, 1991
76. Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Opthalmology 98 (Suppl.):757-765, 1991
77. Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS report no. 9. Opthalmology 98:766-785, 1991
78. American Diabetes Association: Diabetic retinopathy (Position Statement). Diabetes Care 25 (Suppl. 1):S90-S93, 2002
79. Kitzmiller JL, Gav-in LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes: glycemic control prevents excess congenital malformations. JAMA 265:731-736, 1991
80. Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M: Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconception diabetic control: a comparative study. Am J Obstet Gynecol 155:293-297, 1986
81. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA: Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol 77:846-849, 1991
82. Tchobroutsky C, Vray MM, Altman JJ: Risk/benefit ratio of changing late obstetrical strategies in the management of insulin-dependent diabetic pregnancies. Diabete Metab 17:287-294, 1991
83. Willhoite MB, Bennert HW Jr., Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. Diabetes Care 16:450-455, 1993
84. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner R: Preconception care of diabetes, congenital malformations, and spontaneious abortions (Technical Review). Diabetes Care 19:514-541, 1996
85. American Diabetes Association: Preconception care of women with diabetes (Position Statement). Diabetes Care 25 (Suppl. 1):S82 -S84, 2002
86. Colquhoun AJ, Nicholson KG, Botha NT: Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 119:335-341, 1997
87. Advisory Committee on Immunization Practices (ACIP): Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46(no. RR-9):1-25, 1997
88. Advisory Committee on Immunization Practices (ACIP): Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46 (no. RR-8): 1-25, 1997
89. Smith SA, Poland GA: The use of influenza and pneumococcal vaccines in people with diabetes (Technical Review). Diabetes Care 23:95-108, 2000
90. American Diabetes Association: Immunization and the prevention of influenza and pneumococcal disease in people with diabetes (Position Statement). Diabetes Care 25 (Suppl. 1):S117-S119, 2002
91. American Diabetes Association: Care of children with diabetes in the school and day care setting. Diabetes Care 25 (Suppl. 1):S122-S126, 2002